House China Committee Probes Eli Lilly Clinical Trials At Chinese Military Hospitals
House China Committee Chairman John Moolenaar on Tuesday, June 30, 2026, opened a formal investigation into Eli Lilly's China clinical trials by sending the company a records request over studies run at Chinese military hospitals.[1]
The committee says Lilly has run more than 220 clinical studies in China since 2003, including at least 11 in Xinjiang and at least 16 at Chinese military medical centers.[1] The panel is seeking records on ethical safeguards, intellectual property and data protection, and whether any U.S. veterans research took place at People's Liberation Army-linked hospitals.[1] Moolenaar said the committee has no evidence Lilly engaged in illegal activity but described the inquiry as part of a broader U.S.-China biotechnology competition.[1]
In August 2024, the House Select Committee on the Chinese Communist Party sent a letter to the FDA citing public clinicaltrials.gov records. The letter highlighted Lilly's Phase III donanemab study at PLA General Hospital and Air Force Medical University sites. The committee held a March 18, 2026, hearing on China's biotech expansion and supply-chain dominance, and Moolenaar sent parallel June 30 letters to Merck and AbbVie seeking similar records.
China accounted for about 20% of global industry-sponsored clinical trials in 2023, up from 9% in 2018, a shift that lawmakers say heightens the need to scrutinize where and how U.S. companies run foreign trials. Advocates and industry observers on social platforms warned of national-security and human-rights risks, noting reported informed-consent lapses and the risk of transferring biotech intellectual property to military-linked hospitals.
The mainstream summary does not address the significant national security concerns raised by various commentators regarding Eli Lilly's clinical trials at military-linked hospitals. While the summary mentions the House committee's investigation, it overlooks the warnings from experts on social media about the risks of transferring sensitive biotech intellectual property to the Chinese military, a point emphasized by @Unveiled_ChinaX. Additionally, the summary fails to mention documented lapses in informed consent at Chinese trial sites, which @daphnezohar links to broader human rights issues, including the Uyghur Forced Labor Prevention Act. This context highlights a critical dimension of the inquiry that goes beyond mere oversight of clinical practices and touches on ethical and geopolitical implications.
Moreover, the mainstream account does not fully capture the economic backdrop of this investigation. Eli Lilly derived only 3% of its total revenue from China in 2024, suggesting that while the company is engaged in extensive clinical trials in the region, the financial stakes may not be as high as one might assume. This detail, alongside the statistic that China accounted for 20% of global industry-sponsored clinical trials in 2023, indicates a rapidly shifting landscape that lawmakers argue necessitates increased scrutiny of U.S. firms operating in China. These additional perspectives underscore the complexity of the situation, revealing a multifaceted interplay of economic interests, ethical considerations, and national security risks that the mainstream summary does not fully explore.[2][3]
Show source details & analysis (1 source)
📊 Relevant Data
China accounted for approximately 20% of global industry-sponsored clinical trials in 2023, up from 9% in 2018.
China’s Pharmaceutical Ascent: Opportunity for Global Health ... — PMC
Eli Lilly derived 3% of its total revenue from China in 2024.
Eli Lilly and Company — Wikipedia
📌 Key Facts
- On Tuesday, June 30, 2026, Chairman John Moolenaar sent Eli Lilly a letter opening a formal House China committee investigation into its China clinical trial operations.
- The committee says Lilly has been involved in more than 220 clinical studies in China since 2003, including at least 11 in Xinjiang and at least 16 at Chinese military medical centers.
- The panel is seeking information on ethical safeguards, IP and data protection, and any U.S. veterans research conducted at People’s Liberation Army-linked hospitals.
- Moolenaar stated the committee has no evidence Lilly engaged in illegal activity but framed the inquiry as part of a broader U.S.-China biotechnology competition.
📰 Source Timeline (1)
Follow how coverage of this story developed over time